Boston Family Office LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,478 shares of the company’s stock after purchasing an additional 654 shares during the period. Johnson & Johnson accounts for about 1.2% of Boston Family Office LLC’s portfolio, making the stock its 25th largest holding. Boston Family Office LLC’s holdings in Johnson & Johnson were worth $16,553,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently modified their holdings of the company. Solstein Capital LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $30,000. Newton One Investments LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $31,000. Annapolis Financial Services LLC boosted its holdings in shares of Johnson & Johnson by 109.4% during the 2nd quarter. Annapolis Financial Services LLC now owns 312 shares of the company’s stock worth $51,000 after purchasing an additional 163 shares during the last quarter. Lake Point Wealth Management acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $52,000. Finally, Cypress Point Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $58,000. Institutional investors and hedge funds own 67.29% of the company’s stock.
Shares of NYSE JNJ traded down $1.19 during midday trading on Monday, reaching $163.17. The company’s stock had a trading volume of 116,350 shares, compared to its average volume of 7,089,997. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.44. The company has a 50 day moving average price of $171.71 and a 200 day moving average price of $167.61. Johnson & Johnson has a one year low of $133.65 and a one year high of $179.92. The company has a market cap of $429.54 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 2.23 and a beta of 0.71.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Tuesday, August 24th were issued a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 2.60%. The ex-dividend date was Monday, August 23rd. Johnson & Johnson’s dividend payout ratio is currently 52.80%.
Several research firms have recently commented on JNJ. SVB Leerink reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Credit Suisse Group set a $193.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, June 7th. Finally, Morgan Stanley downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 target price for the company. in a research note on Tuesday, September 7th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $190.38.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Further Reading: Earnings Reports
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.